GSK's arthritis alliance with Galapagos delivers third drug candidate
This article was originally published in Scrip
Executive Summary
Galapagos has identified a third preclinical drug candidate in its arthritis alliance with GlaxoSmithKline. Galapagos has also reached milestones for other compounds in the alliance, and together they triggered cash payments of €5.7 million to the Belgian biotech company.